Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for Kaftrio(Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor in Children with Cystic Fibrosis Ages 6 Through 11
November 12, 2021 at 07:27 am EST
Vertex Pharmaceuticals Incorporated announced that the European Medicines Agency?s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.